我们比较了靶区和危及器官 (OAR) 的剂量学特征以及两种加速部分乳腺照射 (APBI) 技术之间的初步临床结果。 44 名诊断为左侧早期乳腺癌的患者接受了 APBI 治疗对使用射波刀 (CK) 的间质近距离放射治疗 (IB) 或立体定向放射治疗 (SBRT) 进行了回顾性评价。比较了靶标和 OAR 的剂量学参数。分析了初步的临床结果，包括肿瘤控制和急性毒性。CK治疗方案显示出更好的心脏剂量节约效果。 CK 和 IB 组在 V150cGy 时对心脏的辐射剂量分别为 24.4% 和 60.4% (p < 0.001)，而 CK 和 IB 组的平均心脏剂量分别为 107.4 cGy 和 204 cGy (p < 0.001) ）。心脏 D1c.c. IB组同侧肺接受的剂量较低，但无显着差异。 CK 组和 IB 组的中位随访时间分别为 28.6 个月和 61.3 个月。在随访期间，没有患者死于乳腺癌或心脏事件。 IB组中的一名患者发生了颈部局部复发事件。CK计划的APBI被证明对心脏有更好的剂量节​​省作用，并且与目标有更好的顺应性和同质性。 CK 是一种非侵入性治疗方法，显示出最小的急性毒性并有望控制肿瘤。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

We compared the dosimetric characteristics of the target and organs at risk (OARs) as well as the preliminary clinical outcomes between two accelerated partial breast irradiation (APBI) techniques.Forty-four patients diagnosed with left-sided early breast cancer who underwent APBI using either interstitial brachytherapy (IB) or stereotactic body radiation therapy (SBRT) with CyberKnife (CK) were retrospectively reviewed. The dosimetric parameters of the target and OARs were compared. Preliminary clinical outcomes, including tumor control and acute toxicity, were analyzed.Treatment plans with CK demonstrated a better cardiac dose-sparing effect. Radiation doses to the heart at V150cGy for the CK and IB groups were 24.4 % and 60.4 %, respectively (p < 0.001), while the mean heart doses for the CK and IB groups were 107.4 cGy and 204 cGy, respectively (p < 0.001). The heart D1c.c. and the ipsilateral lung received a lower dose in the IB group, without any significant differences. The median follow-up time in the CK and IB groups was 28.6 and 61.3 months, respectively. No patients died from either breast cancer or cardiac events during follow-up. A locoregional recurrence event at the neck occurred in one patient within the IB group.APBI planned by CK was shown to have a better dose-sparing effect on the heart, as well as better conformity and homogeneity to the target. CK is a non-invasive treatment which showed minimal acute toxicity and promising tumor control.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.